Compare ADMA Biologics Inc (ADMA) vs J M Smucker Co (SJM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs J M Smucker Co — how do they compare? ADMA Biologics Inc trades at $9.29 (market cap $2.13B), while J M Smucker Co trades at $113.13 (market cap $12.10B). The key difference: J M Smucker Co is far larger — about 5.7× ADMA Biologics Inc's market cap, and J M Smucker Co pays a 3.89% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | SJM | |
|---|---|---|
Market Cap | $2.13B | $12.10B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $117.05 |
52-Week Low | $7.60 | $89.53 |
Enterprise Value | $2.20B | $19.13B |
Dividend Yield | — | 3.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
J.M. Smucker (SJM) trades at $113.24, down 2.61% on the day, with a bullish technical signal from moving averages. The company reported mixed Q4 2026 results, beating EPS estimates but facing sales pressure, with fiscal 2027 revenue guidance projecting a 3-4% decline. Strong cash flow supports a sustainable 4% dividend yield, while valuation metrics show a P/E of 22.05 and P/S of 1.32.
SJM presents a value opportunity with analyst consensus at $122.92 (8.5% upside), but faces headwinds from weak sales visibility and portfolio challenges. The stock's outlook hinges on Uncrustables growth and coffee margin recovery, with balanced risks between dividend stability and competitive pressures in packaged foods.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
